Radiobiology and radiotherapy
C93 – C108
- C93: A retrospective service evaluation of radiotherapy fractionation schedules in cerebral metastases at New Cross Hospital, Wolverhampton
- C94: Mesenchymal stem cells transformed by sequential retroviral transfection do not display radioresistance or upregulated DNA damage responses
- C95: Genetic pathways for the prediction of the effects of ionising radiation: low dose radiosensitivity and risk to normal tissue after radiotherapy
- C96: Over-expression of the base excision repair protein, DNA polymerase beta, is associated with resistance to oxaliplatin chemotherapy and sensitivity to radiotherapy
- C97: The role of radiotherapy for aggressive fibromatosis
- C98: The use of hormone replacement therapy (HRT) for radiation induced premature menopause
- C99: Role of LATS1 in DNA damage signalling
- C100: Micro-CT imaging for anatomical referencing in PET and SPECT: radiation dose, biological damage and image quality
- C101: A mechanistic study of the damage responses evoked by gold nanoparticles, both in the absence and presence of ionising radiation
- C102: Role of intensity modulated radiotherapy in the treatment of soft tissue sarcoma arising close to dose limiting normal structures
- C103: IMPORT LOW re-visited: how strategic trial management has increased average monthly accrual (CRUK06/003)
- C104: IMPORT HIGH development of comprehensive and practical radiotherapy planning solutions may facilitate trial recruitment (CRUK06/003)
- C105: γH2AX: a target for imaging and systemic radiation therapy
- C106: Gold nanoparticles sensitise plasmid DNA and cancer cell lines to broad-spectrum and monochromatic kilo-voltage radiation
- C107: Radiotherapy fraction size sensitivity modulated by DNA repair systems
- C108: Radiolytic markers as biomarkers for breast cancer radiotherapy
